People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akebia Therapeutics, Inc. | — | Biotechnology | Series A | $25.9M | $504.1M | 2011 |
| Invirsa, Inc. | — | Pharmaceuticals | Series A | $9.8M | $9.2M | 2022 |
Robert Shalwitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Shalwitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Campbell Murray | 1 | 9 |
| Wayne Embree | 1 | 6 |
| Ian Howes | 1 | 5 |
| Paul Weiss | 1 | 5 |
| Samuel Lee | 1 | 4 |
| John Rice | 1 | 3 |
| Anupam Dalal | 1 | 2 |
| Joseph Gardner | 1 | 2 |
| Kevin Peters | 1 | 1 |
| Rachael Wingo | 1 | 1 |
| Tim Willis | 1 | 1 |
| Faith Voinovich | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.